In this study, Cloudpharm participated in a study for the discovery of novel agents bearing different scaffolds which may evolve as a new class of AT1 receptor antagonists. Nowadays, AT1 receptor (AT1R) antagonists (ARBs) constitute the one of the most prevalent classes of antihypertensive drugs that modulate the renin-angiotensin system (RAS). Towards this direction, this study resulted in the identification of four compounds with completely diverse chemical scaffolds from other ARBs, with high nanomolar to micromolar affinity.

Bioorg Med Chem. 2016 Sep 15;24(18):4444-4451. doi: 10.1016/j.bmc.2016.07.047. Epub 2016 Jul 22.